Optime Care Expands Partnership With Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE
Express News | Optime Care Expands Partnership With Rigel Pharmaceuticals to Include Commercial Distribution for Tavalisse®
Express News | Rigel Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rigel Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
Rigel Pharmaceuticals Price Target Maintained With a $15.00/Share by Cantor Fitzgerald
Dr. Brian Kotzin Resigns From Rigel Pharmaceuticals' Board
Rigel to Present at the 2024 Cantor Global Healthcare Conference
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
Express News | Rigel Announces First Patient Enrolled in Phase 1B/2 Triplet Therapy Trial of Rezlidhia® (Olutasidenib) in Midh1 Aml
Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA (Olutasidenib) in MIDH1 AML
Express News | Kissei Pharmaceutical Co Ltd - Licensing Agreement for "Olutasidenib", an Acute Myeloid Leukemia Drug
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
H.C. Wainwright analyst Joseph Pantginis maintains $Rigel Pharmaceuticals(RIGL.US)$ with a buy rating, and maintains the target price at $57.According to TipRanks data, the analyst has a success
Express News | Rigel Pharmaceuticals- to Get Product Transfer Price Payments in Mid-20 to Lower-30% Range Based on Tiered Net Sales for Exclusive Supply of Rezlidhia
Express News | Rigel-to Get Upfront Cash Payment of $10.0 Mln With Potential for up to $152.5 Mln in Future Development, Regulatory, Commercial Milestone Payments
With 45% Stake, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Seems to Have Captured Institutional Investors' Interest
Rigel to Participate in Upcoming September Investor Conferences
CORRECTION: HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals (1-for-10 Reverse Stock Split) - Headline Earlier Published on 9th Aug
HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)
Rigel Pharmaceuticals Analyst Ratings